Ergoteles LLC Reduces Position in ChromaDex Co. (NASDAQ:CDXC)

Ergoteles LLC cut its holdings in shares of ChromaDex Co. (NASDAQ:CDXC – Get Rating) by 44.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 127,211 shares of the company’s stock after selling 103,089 shares during the quarter. Ergoteles LLC’s holdings in ChromaDex were worth $156,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Oppenheimer & Co. Inc. lifted its holdings in shares of ChromaDex by 127.3% in the second quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock worth $65,000 after buying an additional 21,900 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its position in shares of ChromaDex by 30.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 97,408 shares of the company’s stock worth $240,000 after purchasing an additional 22,500 shares during the last quarter. Gabelli Funds LLC purchased a new stake in ChromaDex in the third quarter valued at approximately $34,000. XTX Topco Ltd bought a new stake in ChromaDex during the first quarter valued at approximately $76,000. Finally, JPMorgan Chase & Co. grew its stake in ChromaDex by 184.6% in the 1st quarter. JPMorgan Chase & Co. now owns 51,840 shares of the company’s stock worth $128,000 after buying an additional 33,625 shares in the last quarter. 42.81% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Stock Performance

Shares of NASDAQ:CDXC opened at $1.62 on Wednesday. ChromaDex Co. has a 52-week low of $1.15 and a 52-week high of $2.99. The firm has a fifty day moving average of $1.84 and a 200 day moving average of $1.64. The firm has a market capitalization of $120.64 million, a PE ratio of -5.59 and a beta of 1.86.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.50 price objective on shares of ChromaDex in a report on Wednesday, February 1st. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.40.

ChromaDex Profile

(Get Rating)

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.